Search Results - Frederick L. Locke

Refine Results
  1. 1
    CAR T cell therapy for B-cell lymphomas

    CAR T cell therapy for B-cell lymphomas by Julio C. Chávez, Frederick L. Locke

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    How I Treat Cytopenias after CAR T-cell Therapy

    How I Treat Cytopenias after CAR T-cell Therapy by Tania Jain, Timothy S. Olson, Frederick L. Locke

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities

    Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities by Bhagirathbhai Dholaria, Christina A. Bachmeier, Frederick L. Locke

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    CAR T-Cell Therapy in Large B-Cell Lymphoma

    CAR T-Cell Therapy in Large B-Cell Lymphoma by Sattva S. Neelapu, Frederick L. Locke, William Y. Go

    Published 2018
    Get full text
    Carta
    Save to List
    Saved in:
  5. 5
    Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma

    Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma by Frederick L. Locke, William Y. Go, Sattva S. Neelapu

    Published 2019
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy

    The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy by Gregory J. Kimmel, Frederick L. Locke, Philipp M. Altrock

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo

    Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo by Yan Zheng, Yuanyuan Zha, Grégory Driessens, Frederick L. Locke, Thomas F. Gajewski

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma

    Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma by Olalekan O. Oluwole, Jeroen P. Jansen, Vincent Lin, Keith Syson Chan, Sam Keeping, Lynn Navale, Frederick L. Locke

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Efficacy and safety of <scp>CD19</scp>‐directed <scp>CAR‐T</scp> cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the <scp>JULIET</scp>, <scp>ZUMA</scp>‐1, and <scp>TRANSCEND</scp> trials

    Efficacy and safety of <scp>CD19</scp>‐directed <scp>CAR‐T</scp> cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the <scp>JULIET<... by Jason R. Westin, Marie José Kersten, Gilles Salles, Jeremy S. Abramson, Stephen J. Schuster, Frederick L. Locke, Charalambos Andreadis

    Published 2021
    Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations

    CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations by Fabiana Perna, Samir Parekh, Caroline Diorio, Melody Smith, Marion Subklewe, Rakesh Mehta, Frederick L. Locke, Nirali N. Shah

    Published 2024
    Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

    Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial by Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James Signorovitch, Vadim Romanov, Frederick L. Locke, David G. Maloney

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

    Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial by Richard T. Maziarz, Stephen J. Schuster, Vadim Romanov, Elisha S. Rusch, Junlong Li, James Signorovitch, David G. Maloney, Frederick L. Locke

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells

    Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells by Frederick L. Locke, Zahra Mahmoudjafari, Partow Kebriaei, Rebecca Gardner, Matthew J. Frigault, Noelle V. Frey, Krishna V. Komanduri, Miguel‐Angel Perales, Sarah Nikiforow

    Published 2025
    Get full text
    Revisão
    Save to List
    Saved in:
  14. 14
    Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)

    Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel) by Yuan Tian, Justin A. Budka, Frederick L. Locke, Jason R. Westin, Christina To, Gayatri Tiwari, Daqin Mao, Davide Bedognetti, Rhine R. Shen, Jorge Andrade, Simone Filosto

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma

    Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma by Erin Dean, Gregory J. Kimmel, Matthew J. Frank, Ali Bukhari, Nasheed Hossain, Michael D. Jain, Saurabh Dahiya, David B. Miklos, Philipp M. Altrock, Frederick L. Locke

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy

    Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy by Hamza Hashmi, Christina A. Bachmeier, Julio C. Chávez, Jinming Song, Mohammad Hussaini, Gabriel Krivenko, Taiga Nishihori, Hiroshi Kotani, Marco L. Davila, Frederick L. Locke, Michael D. Jain

    Published 2019
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  17. 17
    Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

    Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' by Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Frederick L. Locke, Yi Lin, Nitin Jain, Naval Daver, Alison Gulbis, Sherry Adkins, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma

    End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma by Caron A. Jacobson, Frederick L. Locke, David B. Miklos, Alex F. Herrera, Jason R. Westin, Jennifer Lee, John M. Rossi, Lianqing Zheng, Mauro P. Avanzi, Zachary Roberts, Jennifer K. Sun

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells

    4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells by Emiliano Roselli, Justin C. Boucher, Gongbo Li, Hiroshi Kotani, Kristen Spitler, Kayla Reid, Estelle V. Cervantes, Yannick Bulliard, Nhan Tu, Sae Bom Lee, Bin Yu, Frederick L. Locke, Marco L. Davila

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

    Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma by Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Muñoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J. Kim, Lianqing Zheng, John M. Rossi, Frederick L. Locke

    Published 2020
    Get full text Get full text
    Carta
    Save to List
    Saved in:

Search Tools: